Oligonucleotide API Market size was over USD 2.19 Billion in 2023 and is anticipated to reach USD 7.21 Billion by the end of 2036, growing at around 9.6% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of oligonucleotide api is assessed at USD 2.4 Billion.The growth of the market can be attributed to the rise in laboratory and research institute experiments worldwide. The Increasing use of oligonucleotides for various applications such as gene editing, diagnostics, therapeutics, and so on has driven the surge in interest in APIs across organizations. As per the data by the World Bank, as of 2018, there were 1597 researchers per 1,000,000 people involved in research and development activities across the globe, an increase from 1412 researchers per million in 2015. Further, the growing use of oligonucleotides in the effective treatment of several disorders is another major factor that is estimated to push the market growth further throughout the forecast period.
In addition to these, factors that are believed to fuel the market growth of oligonucleotide API include the worldwide rising proportion of oligonucleotide API in the drug pipeline which is estimated to accelerate the global oligonucleotide API market size in coming years. The oligonucleotide is a new type of therapeutic molecule ideal for treating a variety of diseases. Oligonucleotide base pairs with DNA or RNA to form a structure. In PCR (polymerase chain reaction), oligonucleotides are commonly used as primers. In addition, funding in life science activities, innovative product launches, and drug discovery, along with investments in high-profile big science projects are expected to drive demand for oligonucleotide API during the forecast period. For instance, according to estimates, governments around the world and international organizations are expected to invest a total of more than USD 170 billion on large-scale science projects between 2022 and 2025.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
9.6% |
|
Base Year Market Size (2023) |
USD 2.19 Billion |
|
Forecast Year Market Size (2035) |
USD 7.21 Billion |
|
Regional Scope |
|
End-user (Pharmaceutical Companies, Biotechnology Companies)
The global oligonucleotide API market is segmented and analyzed for demand and supply by end-user into pharmaceutical companies and biotechnology companies. Among these two segments, the pharmaceutical companies segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing adoption of innovative technology by pharmaceutical giants for improving drug efficacy and reducing development costs. For instance, a variety of oligonucleotides has become increasingly popular in the pharmaceutical industry, including antisense oligonucleotides, short-interfering RNAs, splice-switching oligonucleotides, microRNAs, immunostimulatory oligonucleotides, aptamers. The capacity to target the illness gene or the messenger RNAs (mRNAs) that are encoded by it has created new therapeutic possibilities. The length of therapeutic antisense oligonucleotides (ASOs) varies from 18 to 30 base pairs (bp).
API type {Short Interfering RNA (siRNA), Antisense Oligonucleotides, Phosphorodiamidate Morpholino Oligonucleotides (PMO), Aptamers, CpG Oligonucleotides, MiRNA API}
The global oligonucleotide API market is also segmented and analyzed for demand and supply by type into short interfering RNA (siRNA), antisense oligonucleotides, phosphorodiamidate morpholino oligonucleotides (PMO), aptamers, CpG oligonucleotides, MiRNA API, and others. Amongst these segments, the antisense oligonucleotides segment is expected to garner a significant share. The growth of the segment can be attributed to the rising focus on personalized medicine across the globe, along with the high efficiency of antisense for delivering effective results in the treatment. Besides this, antisense oligonucleotides deliver effective outcomes in Alzheimer’s treatment. Thus, spiking cases of Alzheimer’s is another factor that is projected to boost the growth of the segment in coming years. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
By API Type |
|
|
By Marketing Status |
|
|
By End User |
|
North American Market Forecast
The North American oligonucleotide API market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2036. The growth of the market can be attributed majorly to the increased healthcare spending, along with the enhanced healthcare facilities anticipated to fuel the oligonucleotide API market in the region over the forecast period. A recent report from the Centers for Medicare & Medicaid Services revealed that approximately 19.7% of GDP in the United States was spent on healthcare services in 2020, amounting to USD 4.1 trillion in total. In addition to this, surging R&D investments in novel drug discovery and commercialization of oligonucleotide therapies are also expected to further drive the regional market during the forecast period.
Europe Market Forecast
Furthermore, the European oligonucleotide API market is also estimated to display lucrative market growth by the end of 2036. The growth of the market can be attributed to the escalating investment in research and development activities in the region, followed by the presence of major players in the region. For instance, the biopharma sector in Europe region raised around USD 21 billion investment in 2018, and this amount surged by nearly 26% to USD 28 billion in 2019. Moreover, the rising focus on the development of precision medicine for cancer is another significant factor that is projected to boost the market growth further throughout the forecast period in the region.
Ionis Pharmaceuticals, Inc. in collaboration with Biogen Inc., has announced the results of the investigation of the use of antisense oligonucleotide (ASO) for people with C9orf72-associated amyotrophic lateral sclerosis (ALS).
Jazz Pharmaceuticals plc has announced that its Zepzelca (Lurbinectedin) has been approved by the U.S. Food and Drug Administration(FDA), for treating adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?